ClinicalTrials.gg
DrugBiological

Retifanlimab clinical trials

Also written INCMGA00012, MGA012 and Zynyz.

studies test it
44
open now
11
in phase 3
5
first study started
2016

How each study uses retifanlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the retifanlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Mar 2023 · ZYNYZ · BLA 761334 (FDA, Drugs@FDA)
European Union
19 Apr 2024 · Zynyz · EMEA/H/C/006194 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Retifanlimab
36

Brand

Zynyz
4

Development codes

INCMGA00012
26
MGA012
11
INCMGA0012
5

Studies by the year they started

44 studies that test it; most in 2020 (11)

Studies that test retifanlimab, by start year
YearStudies
20161
20184
20195
202011
20214
20225
20234
20243
20251
20266

Who runs them

Industry 16 · Other 28

Incyte Corporation (9) · MacroGenics (5) · Memorial Sloan Kettering Cancer Center (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Washington University School of Medicine (2) · M.D. Anderson Cancer Center (2) · University of Washington (1) · Institut Bergonié (1)

Often tested with

Tested in the same studies.

Epacadostat (3) · Tuparstobart (3) · Verzistobart (3) · Tebotelimab (3) · Allogeneic Autophagosome-enriched Vaccine DPV-001 (1) · Pelareorep (1) · Pemetrexed (1) · Cisplatin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4

Studies that test retifanlimab.

Studies

Open first, then newest update. How each study uses retifanlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 44

See all 44 studies that test retifanlimab →

Given beside what is tested · 25 — retifanlimab is usual care or a partner of the new treatment

Showing 20 of 25.

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call retifanlimab · ClinicalTrials.gg INT002166

  • MeSH (NLM) C000731936retifanlimabOne source NLM
  • UNII (FDA) 2Y3T5IF01ZRETIFANLIMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q117349369retifanlimabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C142168RetifanlimabOne source FDA
  • DrugBank DB15766One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.